Stemedica International Announces Pre-clinical Data of Its Alzheimera s Study

Stemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer's disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells in a pre-clinical animal model of Alzheimer's disease.

http://ift.tt/1uTmzYg